Abstract 22P
Background
The purpose of this study was to evaluate the characteristics and outcomes of early breast cancer patients who underwent skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy without radiotherapy.
Methods
A total 104 patients with early breast cancer who underwent mastectomy with sentinel lymph node biopsy were identified in Korea Ansan University Hospital between 2007 and 2017. 85 total mastectomies (TM), 11 nipple areolar complex-sparing mastectomies (NSM), and 8 Skin-sparing mastectomiesm (SSM) were included. All these patients did not undergo adjuvant radiotherapy on chest wall or axillary area. We divided the patients into two groups, TM group and NSM/SSM group. We retrospectively collected clinitopathologic data for these patients. Locoregional recurrence rate, distant recurrence rate, overall recurrence free survival, and overall survival were determined. All statistical analysis was performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Median follow-up was 53 months. Fifty-five percentage of TM group patients received chemotherapy and 63.7 % of NSM/SSM patients received chemotherapy. Locoregional recurrence free survival was 95.3% vs. 78.9% in TM group and NSM/SSM group (p = 0.037). Locoregional failure rate was significantly high in NSM/SSM group than TM group. Distant recurrence free survival was 97.6% vs. 89.5% in TM group and NSM/SSM group (p = 0.128). Overall recurrence free survival was 92.9% vs. 78.9% in TM group and NSM/SSM group (p = 0.118). Overall survival was 98.8% and 94.7% in TM group and NSM/SSM group (p = 0.289). Total two deaths were observed in enrolled patients, one in TM group and another in NSM/SSM group. One death in TM group was unrelated to breast cancer and cause of death was complication from end-stage renal disease. One death in NSM/SSM group was related to breast cancer.
Conclusions
In conclusion, early breast cancer patients who underwent total mastectomy, skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy had excellent outcomes without additional axillary surgery or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract